Generalized Anxiety Disorder study: SEP-363856
Official title A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder
ClinicalTrials.gov ID: NCT07759128
What this study is testing
What is SEP-363856?
An investigational oral tablet being studied as a potential treatment for generalized anxiety disorder.
Also referred to as Ulotaront.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if the drug works and is safe for people with generalized anxiety disorder.
- Who it's for
- Adults 18 years or older who have generalized anxiety disorder.
- What's involved
- Participants will take either 50 mg, 75 mg, or a placebo of the drug each day and will have regular visits and tests over the study period.
- Time commitment
- The study lasts 8 weeks, with scheduled visits and assessments during that time.
- Phase 3: a large, late-stage study
- Time commitment: about 8 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Male or female participants at least 18 years of age at the time of informed consent
- Primary diagnosis of Generalized Anxiety Disorder (GAD) per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed...
- Body Mass Index (BMI) between 18 and 40 kilograms per square meter (kg/m\^2) (inclusive)
- Participant is willing and able to comply with study procedures and visit schedule
- Medically stable as determined by medical history, physical exam, vital signs, and laboratory tests
You likely can't join if
- Current DSM-5 diagnosis of major depressive episode, post traumatic stress disorder (PTSD), or any psychiatric disorder other than GAD that was the...
- Substance use disorder (excluding nicotine/caffeine) within 12 months prior to screening
- Lifetime history of certain psychiatric disorders (e.g., schizophrenia spectrum disorders, bipolar disorder, obsessive-compulsive disorder...
- Significant suicide risk (e.g., recent suicidal behavior/ideation per Columbia-Suicide Severity Rating Scale [C-SSRS] or MADRS)
- Use of prohibited medications/therapies within protocol-defined timeframes (e.g., certain antipsychotics, mood stabilizers, benzodiazepines...
- Prior exposure to restricted treatments
See the full eligibility criteria
- Male or female participants at least 18 years of age at the time of informed consent
- Primary diagnosis of Generalized Anxiety Disorder (GAD) per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by Mini-International Neuropsychiatric Interview (MINI) and clinical...
- Body Mass Index (BMI) between 18 and 40 kilograms per square meter (kg/m\^2) (inclusive)
- Participant is willing and able to comply with study procedures and visit schedule
- Medically stable as determined by medical history, physical exam, vital signs, and laboratory tests
- Willing and able to discontinue prohibited medications/therapies per protocol
- i) Females of childbearing potential: negative pregnancy test and agreement to use acceptable contraception ii) Males: agreement to follow protocol-defined contraception and reproductive restrictions
- Participant is willing and able to safely discontinue all prohibited medications/therapies/herbal supplements in accordance with the protocol-required washouts prior to baseline/Day 1 and during the trial period. Key
- Current DSM-5 diagnosis of major depressive episode, post traumatic stress disorder (PTSD), or any psychiatric disorder other than GAD that was the primary focus of treatment within 12 months prior to screening
- Substance use disorder (excluding nicotine/caffeine) within 12 months prior to screening
- Lifetime history of certain psychiatric disorders (e.g., schizophrenia spectrum disorders, bipolar disorder, obsessive-compulsive disorder, borderline or antisocial personality disorder)
- Significant suicide risk (e.g., recent suicidal behavior/ideation per Columbia-Suicide Severity Rating Scale [C-SSRS] or MADRS)
- Use of prohibited medications/therapies within protocol-defined timeframes (e.g., certain antipsychotics, mood stabilizers, benzodiazepines, investigational treatments)
- Prior exposure to restricted treatments
- Pregnant or breastfeeding females
- Participation in another investigational study within 180 days (or more than [\>] 1 trial in last year)
- Known history of human immunodeficiency virus seropositivity, hepatitis B or C
The study team makes the final eligibility decision.
Where it is enrolling
- Tucson, Arizona, United States
- Encino, California, United States
- Sherman Oaks, California, United States
- Washington D.C., District of Columbia, United States
- Gainesville, Florida, United States
- Jacksonville, Florida, United States
- Maitland, Florida, United States
- Warrenville, Illinois, United States
- New Orleans, Louisiana, United States
- Boston, Massachusetts, United States
- Las Vegas, Nevada, United States
- New York, New York, United States
- Independence, Ohio, United States
- Oklahoma City, Oklahoma, United States
- Dallas, Texas, United States
- DeSoto, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 8 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Tucson, Arizona, United States; Encino, California, United States; Sherman Oaks, California, United States; Washington D.C., District of Columbia, United States; Gainesville, Florida, United States; Jacksonville, Florida, United States and 10 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.